Cargando…
Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy
SIMPLE SUMMARY: Ovarian cancer is among the most malignant gynecologic cancers, in part because intraperitoneal recurrence occurs with high frequency due to occult metastasis. We have demonstrated a metastasis-inhibitory effect of plasma-activated medium (PAM) in ovarian cancer cells. Here, we inves...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962102/ https://www.ncbi.nlm.nih.gov/pubmed/33799991 http://dx.doi.org/10.3390/cancers13051141 |
_version_ | 1783665405328359424 |
---|---|
author | Nakamura, Kae Yoshikawa, Nobuhisa Mizuno, Yuko Ito, Miwa Tanaka, Hiromasa Mizuno, Masaaki Toyokuni, Shinya Hori, Masaru Kikkawa, Fumitaka Kajiyama, Hiroaki |
author_facet | Nakamura, Kae Yoshikawa, Nobuhisa Mizuno, Yuko Ito, Miwa Tanaka, Hiromasa Mizuno, Masaaki Toyokuni, Shinya Hori, Masaru Kikkawa, Fumitaka Kajiyama, Hiroaki |
author_sort | Nakamura, Kae |
collection | PubMed |
description | SIMPLE SUMMARY: Ovarian cancer is among the most malignant gynecologic cancers, in part because intraperitoneal recurrence occurs with high frequency due to occult metastasis. We have demonstrated a metastasis-inhibitory effect of plasma-activated medium (PAM) in ovarian cancer cells. Here, we investigated whether PAM inhibits intraperitoneal metastasis. We observed that PAM induced macrophages’ infiltration into the disseminated lesion, which was co-localized with inducible nitric oxide synthase (iNOS)-positive signal, indicating that PAM might induce M1-type macrophages. We also observed that intraperitoneal washing with plasma-activated lactate Ringer’s solution (PAL) significantly improved the overall survival rate in an ovarian cancer mouse model. Intraperitoneal washing therapy might be effective to improve clinical outcomes of ovarian cancer. ABSTRACT: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The major cause of EOC’s lethality is that intraperitoneal recurrence occurs with high frequency due to occult metastasis. We had demonstrated that plasma-activated medium (PAM) exerts a metastasis-inhibitory effect on ovarian cancer in vitro and in vivo. Here we investigated how PAM inhibits intraperitoneal metastasis. We studied PAM’s inhibition of micro-dissemination onto the omentum by performing in vivo imaging in combination with a sequential histological analysis. The results revealed that PAM induced macrophage infiltration into the disseminated lesion. The iNOS-positive signal was co-localized at the macrophages in the existing lesion, indicating that PAM might induce M1-type macrophages. This may be another mechanism of the antitumor effect through a PAM-evoked immune response. Intraperitoneal lavage with plasma-activated lactate Ringer’s solution (PAL) significantly improved the overall survival rate in an ovarian cancer mouse model. Our results demonstrated the efficiency and practicality of aqueous plasma for clinical applications. |
format | Online Article Text |
id | pubmed-7962102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79621022021-03-17 Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy Nakamura, Kae Yoshikawa, Nobuhisa Mizuno, Yuko Ito, Miwa Tanaka, Hiromasa Mizuno, Masaaki Toyokuni, Shinya Hori, Masaru Kikkawa, Fumitaka Kajiyama, Hiroaki Cancers (Basel) Article SIMPLE SUMMARY: Ovarian cancer is among the most malignant gynecologic cancers, in part because intraperitoneal recurrence occurs with high frequency due to occult metastasis. We have demonstrated a metastasis-inhibitory effect of plasma-activated medium (PAM) in ovarian cancer cells. Here, we investigated whether PAM inhibits intraperitoneal metastasis. We observed that PAM induced macrophages’ infiltration into the disseminated lesion, which was co-localized with inducible nitric oxide synthase (iNOS)-positive signal, indicating that PAM might induce M1-type macrophages. We also observed that intraperitoneal washing with plasma-activated lactate Ringer’s solution (PAL) significantly improved the overall survival rate in an ovarian cancer mouse model. Intraperitoneal washing therapy might be effective to improve clinical outcomes of ovarian cancer. ABSTRACT: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The major cause of EOC’s lethality is that intraperitoneal recurrence occurs with high frequency due to occult metastasis. We had demonstrated that plasma-activated medium (PAM) exerts a metastasis-inhibitory effect on ovarian cancer in vitro and in vivo. Here we investigated how PAM inhibits intraperitoneal metastasis. We studied PAM’s inhibition of micro-dissemination onto the omentum by performing in vivo imaging in combination with a sequential histological analysis. The results revealed that PAM induced macrophage infiltration into the disseminated lesion. The iNOS-positive signal was co-localized at the macrophages in the existing lesion, indicating that PAM might induce M1-type macrophages. This may be another mechanism of the antitumor effect through a PAM-evoked immune response. Intraperitoneal lavage with plasma-activated lactate Ringer’s solution (PAL) significantly improved the overall survival rate in an ovarian cancer mouse model. Our results demonstrated the efficiency and practicality of aqueous plasma for clinical applications. MDPI 2021-03-07 /pmc/articles/PMC7962102/ /pubmed/33799991 http://dx.doi.org/10.3390/cancers13051141 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nakamura, Kae Yoshikawa, Nobuhisa Mizuno, Yuko Ito, Miwa Tanaka, Hiromasa Mizuno, Masaaki Toyokuni, Shinya Hori, Masaru Kikkawa, Fumitaka Kajiyama, Hiroaki Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy |
title | Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy |
title_full | Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy |
title_fullStr | Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy |
title_full_unstemmed | Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy |
title_short | Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy |
title_sort | preclinical verification of the efficacy and safety of aqueous plasma for ovarian cancer therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962102/ https://www.ncbi.nlm.nih.gov/pubmed/33799991 http://dx.doi.org/10.3390/cancers13051141 |
work_keys_str_mv | AT nakamurakae preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy AT yoshikawanobuhisa preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy AT mizunoyuko preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy AT itomiwa preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy AT tanakahiromasa preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy AT mizunomasaaki preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy AT toyokunishinya preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy AT horimasaru preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy AT kikkawafumitaka preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy AT kajiyamahiroaki preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy |